TD Cowen analyst Dan Brennan maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price tar

The presentations build upon the strong evidence base with new use cases and clinical comparisons, i

New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic

BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cance

Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, today announced strategic pro

Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagno

Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps im

Biodesix, Inc. (NASDAQ: BDSX - Get Free Report) has received a consensus recommendation of "Moderate

LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagn

Does Biodesix, Inc. (BDSX) have what it takes to be a top stock pick for momentum investors? Let's f

The consensus price target hints at a 26.7% upside potential for Biodesix (BDSX). While empirical re

Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more co

Biodesix NASDAQ: BDSX said its commercial expansion, broader primary care outreach and recently publ

Biodesix (BDSX) is at a 52-week high, but can investors hope for more gains in the future? We take a

The consensus price target hints at a 31.9% upside potential for Biodesix (BDSX). While empirical re

Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the

HC Wainwright & Co. analyst Yi Chen maintains Biodesix (NASDAQ:BDSX) with a Buy and raises th

Biodesix, Inc. (BDSX) Q2 2026 Earnings Call Transcript

Biodesix NASDAQ: BDSX reported second-quarter 2026 revenue growth of 34% year over year, supported b

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus E

Biodesix (NASDAQ:BDSX) affirms FY2026 sales outlook from $108.000 million-$114.000 million to $108.0

Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in

LOUISVILLE, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagno

bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock of

LOUISVILLE, Colo., July 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagno

Shares of Biodesix, Inc. (NASDAQ: BDSX - Get Free Report) have received an average rating of "Modera

Roth Capital analyst Max Masucci initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating a

Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the

Top Wall Street analysts changed outlook on top names. Find all rating changes on Benzinga's ana

HC Wainwright & Co. analyst Yi Chen initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy r

Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the

Biodesix (NASDAQ:BDSX) raises FY2026 sales outlook from $106.000 million-$112.000 million to $108.00

Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.81) per share which beat the analyst consens

2026 Financial OutlookThe Company anticipates generating between $106-112 million in total revenue i

Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.49) per share which beat the analyst consens

XOM: -1.5% | Trump 'Inclined' To Keep Exxon Mobil Out Of Venezuela: 'Didn't Like The